CD4 and myeloid sarcoma: CD28 can promote the increase of c-myc and Glucose transporter type 1 (Glut1) in CD4+ T cells of MS patients by activating the PI3K-AKT pathway, upregulating glycolysis and increasing Th17 cell-associated inflammatory cytokine expression (42).